DAFTAR PUSTAKA

1. World Health Organization. International Statistical Classification of

Diseases and Related Health Problems. 10th Revision. World Health
Organization. 2010.
2. Alkema, Leontine, et al. "Global, regional, and national levels and trends in
maternal mortality between 1990 and 2015, with scenario-based projections
to 2030: a systematic analysis by the UN Maternal Mortality Estimation
Inter-Agency Group." The Lancet 387.. 2016. 10017: 462-474.
3. Reinke, Evelyn, and Jörg Haier Supriyatiningsih. "Maternal mortality as a
Millennium Development Goal of the United Nations: a systematic
assessment and analysis of available data in threshold countries using
Indonesia as example." Journal of global health 7.1. 2017.
4. World Health Organization. World Health Statistics 2018: Monitoring
Health for the SDGs sustainable development goals. World Health
Organization. 2018.
5. World Health Organization. WHO recommendations for prevention and
treatment of pre-eclampsia and eclampsia. World Health Organization.
2013.
6. World Health Organization. WHO recommendations for prevention and
treatment of pre-eclampsia and eclampsia. World Health Organization.
2011.
7. Say, Lale, et al. Global causes of maternal death: a WHO systematic
analysis. The Lancet Global Health. 2014. 2.6: e323-e333.
8. –
9. –
10. Rich-Edwards, Janet W., Roberta B. Ness, and James M. Roberts.
Epidemiology of pregnancy-related hypertension. Chesley's Hypertensive
Disorders in Pregnancy. Academic Press. 2015.p:37-55.
11. Maynard, Sharon E., et al. Excess placental soluble fms-like tyrosine kinase
1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and
proteinuria in preeclampsia. The Journal of clinical investigation. 2003.
111.5: 649-658.
12. Weissgerber, Tracey L., et al. Vascular pool of releasable soluble VEGF
receptor-1 (sFLT1) in women with previous preeclampsia and
uncomplicated pregnancy. The Journal of Clinical Endocrinology &
Metabolism. 2014. 99.3: 978-987.
13. Karumanchi, S. Ananth, Phyllis August, and Tiina Podymow. Renal
complications in normal pregnancy. Comprehensive clinical nephrology.
Mosby. 2010. p:504-515.
14. Phipps, Elizabeth, et al. Preeclampsia: updates in pathogenesis, definitions,
and guidelines. Clinical Journal of the American Society of Nephrology.
2016. 11.6: 1102-1113.
15. Maynard, Sharon E., and S. Ananth Karumanchi. Angiogenic factors and
preeclampsia. Seminars in nephrology. Vol. 31. No. 1. WB Saunders. 2011.
16. Balan, Adelina, et al. The effects of pravastatin on the normal human
placenta: lessons from ex-vivo models. PloS one . 2017. 12.2: e0172174.
17. Brownfoot, Fiona C., et al. Effects of simvastatin, rosuvastatin and
pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble
endoglin (sENG) secretion from human umbilical vein endothelial cells,
primary trophoblast cells and placenta. BMC pregnancy and childbirth.
2016. 16.1: 117.
18. Brownfoot, Fiona C., et al. Effects of pravastatin on human placenta,
endothelium, and women with severe preeclampsia. Hypertension. 2015.
66.3: 687-697.
19. Tu’uhevaha, J., et al. Combining metformin and esomeprazole is additive in
reducing sFlt-1 secretion and decreasing endothelial dysfunction–
implications for treating preeclampsia. PloS one. 2018. 13.2: e0188845.
20. Onda, Kenji, et al. Proton pump inhibitors decrease soluble fms-like
tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension,
and rescue endothelial dysfunction. Hypertension. 2017. 69.3: 457-468.
21. American College of Obstetricians and Gynecologists. Hypertension in
pregnancy. Report of the American College of Obstetricians and
Gynecologists’ task force on hypertension in pregnancy. Obstetrics and
gynecology. 2013. 122.5: 1122.
22. –
23. –
24. Jeyabalan, Arun. Epidemiology of preeclampsia: impact of obesity.
Nutrition reviews. 2013. 71suppl_1: S18-S25.
25. Abalos, Edgardo, et al. Global and regional estimates of preeclampsia and
eclampsia: a systematic review. European Journal of Obstetrics &
Gynecology and Reproductive Biology. 2013. 170.1: 1-7.
26. D'Oriaa, Rossella, et al. Pregnancy Hypertension: An International Journal
of Women’s Cardiovascular Health. 2015.
27. Opitasari, Cicih, and Lelly Andayasari. Parity, education level and risk for
(pre-) eclampsia in selected hospitals in Jakarta. Health Science Journal of
Indonesia. 2014. 5.1: 35-39.
28. –
29. English, Fred A., Louise C. Kenny, and Fergus P. McCarthy. Risk factors
and effective management of preeclampsia. Integrated blood pressure
control. 2015. 8: 7.
30. Kraus, Daniel M., et al. Cigarette smoke-induced placental adrenomedullin
expression and trophoblast cell invasion. Reproductive Sciences. 2014.
21.1: 63-71.
31. Boyd, Heather A., et al. Associations of personal and family preeclampsia
history with the risk of early-, intermediate-and late-onset
preeclampsia. American journal of epidemiology. 2013. 178.11: 1611-
1619.
32. Gathiram, P., and J. Moodley. Pre-eclampsia: its pathogenesis and
pathophysiolgy. Cardiovascular journal of Africa. 2016. 27.2: 71.
33. Mirković, Ljiljana, Lazar Nejković, and Jelena Micić. A new
pathophysiological concept and new classification of pre-eclampsia.
Vojnosanitetski pregled. 2018. 75.1: 83-94.
34. Salan, Yosef Dwi Cahyadi. Biomarker Terkini Dalam USAha Memprediksi
Preeklampsia. Berkala Kedokteran Unlam. 2017. 13.1: 119-128.
35. Staff, Anne Cathrine, et al. Preeclampsia and uteroplacental acute atherosis:
immune and inflammatory factors. Journal of reproductive immunology.
2014. 101: 120-126.
36. Founds, Sandra A., et al. Altered global gene expression in first trimester
placentas of women destined to develop preeclampsia. Placenta. 2009. 30.1:
15-24.
37. Pollheimer, J., V. Fock, and M. Knöfler. Review: the ADAM
metalloproteinases–novel regulators of trophoblast invasion?. Placenta.
2014. 35: S57-S63.
38. Cines, Douglas B., et al. Endothelial cells in physiology and in the
pathophysiology of vascular disorders. Blood.1998. 91.10: 3527-3561.
39. van Mourik, Jan A., et al. von Willebrand factor propeptide in vascular
disorders: A tool to distinguish between acute and chronic endothelial cell
perturbation. Blood. 1999. 94.1: 179-185.
40. Dharma, Rahajuningsih, Noroyono Wibowo, and Hessyani PT Raranta.
Disfungsi endotel pada preeklampsia. Makara Kesehatan. 2005. 9.2: 63-65.
41. Danianto, Ario, and Ernawati Ernawati. Perbedaan Kadar IL-10 pada
Preeklampsia Tipe Dini dan Lambat. Majalah Obstetri & Ginekologi. 2015.
23.3: 106-111.
42. Matthiesen, Leif, et al. Immunology of preeclampsia. Immunology of
pregnancy. Vol. 89. Karger Publishers. 2005. p:49-61.
43. Faas, Marijke M., Floor Spaans, and Paul De Vos. Monocytes and
macrophages in pregnancy and pre-eclampsia. Frontiers in immunology.
2014. 5: 298.
44. Chung, Jin-Young, et al. Differential expression of VEGF, EG-VEGF, and
VEGF receptors in human placentas from normal and pre-eclamptic
Pregnancies. The Journal of Clinical Endocrinology and Metabolism. 2004.
89.5: 2484.
45. Herse, Florian, et al. Prevalence of agonistic autoantibodies against the
angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a
gestational age–matched case study. Hypertension. 2009. 53.2: 393-398.
46. Parrish, Marc R., et al. The effect of immune factors, tumor necrosis factor-
α, and agonistic autoantibodies to the angiotensin II type I receptor on
soluble fms-like tyrosine-1 and soluble endoglin production in response to
hypertension during pregnancy. American journal of hypertension. 2010.
23.8: 911-916.
47. Patigaroo, FA., Siddiqui, AH., Gulati, R., Mohsin, Z. Tumor Necrosis
Factor Alpha in Preeclampsia. International Journal of Basic and Applied
Physiology 2014;2(1)
48. Pinheiro, MB., Filho, OA., Mota, AP., Alpoim, PN., Godoi, LC., Silveira,
AC., et al. Severe Preeclampsia Goes Along with A Cytokine Network
 Disturbance Towards A Systematic Inflammatory State. Cytokine
2013;62:165-173
49. Puppala, M., Kalpana, VL., Anuradha, A., Sushma, M., Sudhakar, G.,
Polipalli, SK. Association of Tumor Necrosis Factor-Alpha and Interleukin-
6 Gene Polymorphisms with Preeclampsia. International Journal of
Bioassays 2016;5(2):4744-4744
50. Udenze, I., Amadi, C., Awolola, N., Makwe, CC. The Role of Cytokines as
Inflammatory Mediators in Preeclampsia. Pan African Medical Journal
2015;20:219
51. Vitoratos, N., Economou, E., Iavazzo, C., Panoulis, K., Creatsas, G.
Maternal Serum Levels of TNF-Alpha and IL-6 Long After Delivery in
Preeclamptic and Normotensive Pregnant Women. Mediators of
Inflammation 2010
52. Xie, C., Yao, MZ., Liu, JB., Xiong, LK. A Meta-Analysis of Tumor
Necrosis Factor-Alpha, Interleukin-6, and Interleukin-10 in Preeclampsia.
Cytokine 2011;56:550-559
53. Gandhi S, Sun D, Park AL, Hladunewich M, Silversides CK, Ray JG. The
pulmonary edema preeclampsia evaluation (PEPE) study. Journal of
Obstetrics and Gynaecology Canada. 2014 Dec 1;36(12):1065-70.
54. Dennis AT, Solnordal CB. Acute pulmonary oedema in pregnant women.
Anaesthesia. 2012 Jun;67(6):646-59.
55. Oosterhof H, Voorhoeve PG, Aarnoudse JG. Enhancement of hepatic artery
resistance to blood flow in preeclampsia in presence or absence of HELLP
syndrome (hemolyis, elevated liver enzymes, and low platelets). American
journal of obstetrics and gynecology. 1994 Aug 1;171(2):526-30.
56. Lafayette R. The kidney in preeclampsia. Kidney international. 2005 Mar
1;67(3):1194-203.
57. Meyer NL, Mercer BM, Friedman SA, Sibai BM. Urinary dipstick protein:
a poor predictor of absent or severe proteinuria. American journal of
obstetrics and gynecology. 1994 Jan 1;170(1):137-41.
58. Lee W, Gonik B, Cotton DB. Urinary diagnostic indices in preeclampsia-
associated oliguria: Correlation with invasive hemodynamic monitoring.
American journal of obstetrics and gynecology. 1987 Jan 1;156(1):100-3.
59. Verdonk K, Visser W, Van Den Meiracker AH, Danser AJ. The renin–
angiotensin–aldosterone system in pre-eclampsia: the delicate balance
between good and bad. Clinical Science. 2014 Apr 1;126(8):537-44.
60. Kahramonovich AF. Features of renal function and some indicators of
homeostasis in women with mild preeclampsia. European science review.
2015(5-6).
61. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia.
InSeminars in perinatology 2012 Feb 1 (Vol. 36, No. 1, pp. 56-59). WB
Saunders.
62. Salan YDC, Biomarker Terkini Dalam Usaha Memprediksi Preeklampsia.
Berkala Kedokteran, Vol.13, No.1,2017: 119-128
63. Hassan MF, Nancy, Rund MA, Salama AH. An Elevated Maternal Plasma
Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at
 Midtrimester Is a Useful Predictor for Preeclampsia.Hindawi Publishing
Corporation Obstetrics and Gynecology International. 2013,
64. Carmen R, Bacârea A, Hutanu A, Gabor R, Dobreanu M. Placental Growth
Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and
IL-16 as Biomarkers in Preeclampsia. Hindawi Publishing Corporation
Obstetrics and Gynecology International. 2016
65. Amel A.F. El-Sayed. Preeclampsia: A Review Of The Pathogenesis And
Possible Management Strategies Based On Its Pathophysiological
Derangements.Taiwanese Journal Of Obstetrics & Gynecology 56.2017;
593-598
66. Roberts JM, Rajakumar A. Preeclampsia and Soluble fms-Like Tyrosine
Kinase 1. J Clin Endocrinol Metab. 2009; 94(7): 2252–2254
67. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-
Like Tyrosine Kinase 1 And Endothelial. Dysfunction In The Pathogenesis
Of Preeclampsia.. International Pediatric Research Foundation. 2005
68. Hagmann H, Thadhani R,Benzing T,Karumanchi, Stepan H. The Promise
of Angiogenic Markers for the Early Diagnosis and Prediction of
Preeclampsia. Clinical Chemistry . 2012; 837–845
69. Lopez-Novoa J. M. (2012). Angiogenic stimuli and endoglin absence
induces brain arteriovenous malformations: are local endoglin deletion and
angiogenesis the ‘second hit’ that is necessary for arteriovenous
malformations formation in HHT-1? Cerebrovasc.
Dis. 33:548 10.1159/000338772
70. Rodriguez-Barbero A, Obreo J, Eleno N, Rodriguez A, Bernabeu C, Lopez-
Novoa JM. Endoglin expression in human and rat mesangial cells and its
upregulation by TGF-beta 1. Biochemical and Biophysical Research
Communications. 2001;282 (1):142–147
71. Nikuei P, Rajaei M, Malekzadeh L et al. Accuracy of Soluble Endoglin for
Diagnosis of Preeclampsia and its severity. Iran Biomed J. 2017;21(5):312-
30
72. Karumanchi SA. Angiogenic factors in preeclampsia: from diagnosis to
therapy. Hypertension. 2016 Jun;67(6):1072-9.
73. –
74. –
75. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties
of statins: an update. Fundamental & clinical pharmacology. 2005
Feb;19(1):117-25.
76. Hatanaka T. Clinical pharmacokinetics of pravastatin. Clinical
pharmacokinetics. 2000 Dec 1;39(6):397-412.
77. Haruyama H, Kuwano H, Kinoshita T, et al. Structure elucidation of the
bioactive metabolites of ML-236B (mevastatin) isolated from dog urine.
Chem Pharm Bull 1986; 34: 1459-67 28.
78. Matsuoka T, Miyakoshi S, Tanzawa K, et al. Purification and
characterization of cytochrome P-450sca from Streptomyces carbophilus:
ML-236B (compactin) induces a cytochrome P450sca in Streptomyces
carbophilus that hydroxylates ML236B to pravastatin sodium (CS-514), a
 tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A
reductase. Eur J Biochem 1989; 184: 707-13
79. Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z,
Easterling TR, Haas DM, Haneline LS, Caritis SN, Venkataramanan R.
Safety and pharmacokinetics of pravastatin used for the prevention of
preeclampsia in high-risk pregnant women: a pilot randomized controlled
trial. American journal of obstetrics and gynecology. 2016 Jun
1;214(6):720-e1.
80. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and
pharmacodynamics of pravastatin alone and with cholestyramine in
hypercholesterolemia. Clin Pharmacol Ther 1990; 48: 201-7
81. Serajuddin ATM, Ranadive SA, Mahoney EM. Relative lipophilicities,
solubilities, and structure-pharmacological considerations of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin,
lovastatin, mevastatin, and simvastatin, J Pharm Sci 1991; 80: 830-4
82. Komai T, Kawai K, Tokui T, et al. Disposition and metabolism of
pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab
Pharmacokinet 1992; 17: 103-13
83. Wang CY, Ping YL dan James KL. Pleiotropic effects of statin therapy:
molecular mechanisms and clinical results. Mol Med. 2008 January ; 14(1):
37–44.
84. Girardi G. Can statins prevent pregnancy complications? J Reprod Immunol
2014;101‑102:161‑7.
85. Katsi V, Georgios G, Manolis SK, Loannis Z, Thomas M, Athanasios JM,
et.al. The Role of Statins in Prevention of Preeclampsia: A Promise for the
Future?. Frontiers in Pharmacology. 2017; 5 (8).
86. Huai, J, Zi Y, Yan YH, Guang JW. Different Effects of Pravastatin on
Preeclampsia‑like Symptoms in Different Mouse Models. Chinese Medical
Journal.2018;5 (131).
87. Costantine MM dan Kirsten C. Pravastatin for the Prevention of
Preeclampsia in High-Risk Pregnant Women. Obstet Gynecol. 2013
February ; 121(201).
88. Bauer AJ, Banek CT, Needham K, Gillham H, Capoccia S, Regal JF, et al.
Pravastatin attenuates hypertension, oxidative stress, and angiogenic
imbalance in rat model of placental ischemia‑induced hypertension.
Hypertension 2013;61:1103‑10.
89. Fox, K. A., Longo, M., Tamayo, E., Kechichian, T., Bytautiene, E.,
Hankins, G. D., et al. Effects of pravastatin on mediators of vascular
function in a mouse model of soluble Fms-like tyrosine kinase-1-induced
preeclampsia. 2011.
90. Lefkou, E., Mamopoulos, A., Fragakis, N., Dagklis, T., Vosnakis, C.,
Nounopoulos, E., et al. Clinical improvement and successful pregnancy in
a preeclamptic patient with antiphospholipid syndrome treated with
pravastatin. Hypertension 63, 2014 : 118–9.
91. Spencer CM, Faulds D. Esomeprazole. Drugs. 2000 Aug 1;60(2):321-9.
 92. McKeage K, Blick SK, Croxtall JD, Lyseng-Williamson KA, Keating GM.
Esomeprazole. Drugs. 2008 Aug 1;68(11):1571-607.
93. McQuaid KR,. Drug Used in The Treatment of Gastrointestinal Disease. In:
Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical
Pharmacology. 11th Ed. New York: McGraw Hill.2009.p.1071-5
94. Pang SH, Graham DY. A clinical guide to using intravenous proton-pump
inhibitors in reflux and peptic ulcers. Therapeutic advances in
gastroenterology. 2010 Jan;3(1):11-22.
95. Cluver C, Hannan N, van Papendorp E, Hiscock R, Mol B, Theron G, Hall
D, Rensburg M, Beard S, Schubert P, Walker S. 34: Th Pre-eclampsia
Intervention with Esomeprazole trial (PIE trial). American Journal of
Obstetrics & Gynecology. 2018 Jan 1;218(1):S26-7.
96. Gill SK, O'brien L, Einarson TR, Koren G. The safety of proton pump
inhibitors (PPIs) in pregnancy: a meta-analysis. The American journal of
gastroenterology. 2009 Jun;104(6):1541.
97. Davies M, Wilton LV, Shakir SA. Safety profile of esomeprazole. Drug
safety. 2008 Apr 1;31(4):313-23.
98. UNC. Basic Rat Handling and Technique Workshop, 2018.
99. De Rijk, et al. Pregnancy dating in the rat: placental morphology and
maternal blood parameters. Toxicologic Pathology vol 30. 2002. 271-282.
100. Soares MJ, et al. Rat placentation: An experimental model for investigating
the hemochorial maternal-fetal interface. Placenta Journal. 2012. 233-243.
101. Harmon et al. IL-10 supplementation increases Tregs and decreases
hypertension in the RUPP rat model of preeclampsia. Hypertens
Pregnancy. 2016. 291-306.
102. Podjarny E, et al. Animal Models of Preeclampsia. Semin Nephrol NIH
Public Access. 2004. 596 – 606.
103. Schooley, et al. Magnesium Deficiency During Pregnancy in Rats Increases
Systolic Blood Pressure and Plasma Nitrite. American Journal of
Hypertension. 2002. 1081-1086.
104. Gong et al. Curcumin improves LPS-induced preeclampsia-like phenotype
in rat by inhibiting the TLR4 signaling pathway. Placenta Journal. 2016.
45-52.
105. Gangwar, et al. Noninvasive measurement of systolic blood pressure in
rats: A novel technique. Indian Journal of Pharmacology. 2014. 351-352.
106. Podjarny E, et al. Animal Models of Preeclampsia. Semin Nephrol NIH
Public Access. 2004. 596 – 606.
107. McMcarthy, et al. Animal models of preeclampsia; uses and limitations.
Placental Journal. 2011. 413-419.
108. LaMarca B, et al. Hypertension in response to autoantibodies to the
angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-
1. Hypertension 54: 905–909, 2009
109. Sakawi, et al. Evaluation of Low-dose Endotoxin Administration during
Pregnancy as a Model of Preeclampsia. American Society of
 Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. 2000. 93:1446–
55
110. Pennington KA, et al. Preeclampsia: multiple approaches for a
multifactorial disease. Disease Models & Mechanisms. 2011. 5(1), 9–18.
111. Xue, P. (2015). Single Administration of Ultra-Low-Dose
Lipopolysaccharide in Rat Early Pregnancy Induces TLR4 Activation in
the Placenta Contributing to Preeclampsia. PLOS ONE. 10(4)
112. Amel A.F. El-Sayed. Preeclampsia: A Review Of The Pathogenesis And
Possible Management Strategies Based On Its Pathophysiological
Derangements.Taiwanese Journal Of Obstetrics & Gynecology 56.2017;
593-598
113. Novus Biologicals.Immunohistochemistry (IHC) Handbook.2017 Putra,
2013
114. Kabiraj A, Gupta J et al. Principle and Techniques of
Immunohistochemistry- A Review. International Journal of Biological &
Medical Research, 2015 ; 6(3): 5204-5210
115. Notoatmodjo S. Metodologi Penelitian Kesehatan. Rineka Cipta. Jakarta.
2012